source
- RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPACRare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2BArgenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases. The Belgian-Dutch pharma said Monday it will pay $…